Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guarneri

Showing results (1331-1340 of 1,433) with videos related to

Pageof 144
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Journal of Clinical Medicine|January 23, 2024
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Leukemia & Lymphoma|February 15, 2021
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphomaNina Orfali, Yuliya Jhanwar, Calvin Koo, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 2, 2025
Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patientsRuggero Ponz de Leon Pisani, Livia Archibugi, Pilar Lazzano, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, Carlo Alberto Giorgi, Saverio Cinieri, et al.
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Eclinicalmedicine|January 7, 2026
Incidence of non-colorectal/endometrial malignancies in individuals with Lynch syndrome: a retrospective cohort studySilvia Negro, Francesco Celotto, Francesca Schiavi, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Critical Reviews in Oncology/Hematology|June 9, 2019
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relativesStefania Gori, Massimo Barberis, Maria Angela Bella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Pageof 144

Showing results (1331-1340 of 1,433) with videos related to

Sort By:
Pageof 144
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Journal of Clinical Medicine|January 23, 2024
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Leukemia & Lymphoma|February 15, 2021
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphomaNina Orfali, Yuliya Jhanwar, Calvin Koo, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 2, 2025
Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patientsRuggero Ponz de Leon Pisani, Livia Archibugi, Pilar Lazzano, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, Carlo Alberto Giorgi, Saverio Cinieri, et al.
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Eclinicalmedicine|January 7, 2026
Incidence of non-colorectal/endometrial malignancies in individuals with Lynch syndrome: a retrospective cohort studySilvia Negro, Francesco Celotto, Francesca Schiavi, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Critical Reviews in Oncology/Hematology|June 9, 2019
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relativesStefania Gori, Massimo Barberis, Maria Angela Bella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Pageof 144